An Open-Label, non-Randomized, Multi-Center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging with [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-Mortem Histopathology

Principal Investigator

Marc Seltzer

Study Number

STUDY02002405

Summary

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Phase

III

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms